Clinical Evidence: Weight Loss
Phase 2 trial data, dose-response curves, and the TRIUMPH Phase 3 program
The Trial Data
In 2023, the New England Journal of Medicine published the Phase 2 retatrutide results that stunned the obesity field: participants on the highest dose lost an average of 24.2% of their body weight in just 48 weeks -- the most ever recorded for an injectable anti-obesity medication. This unit walks you through the trial design, dose-response data, and what the Phase 3 TRIUMPH program aims to confirm.
Compare Dose-Response Data
Interact with the Phase 2 trial results to compare weight loss outcomes, response rates, and side effect profiles across all four dose tiers.